Ironwood Pharmaceuticals, Inc. (NasdaqGS: IRWD)
Health Care · Biotechnology · US
$4.37
+1.86% today · +237.8% 1Y
Ironwood Pharmaceuticals, Inc. (NasdaqGS: IRWD) operates in the Biotechnology industry within the Health Care sector. The company is valued at $708.88M and employs 100 people.
Over the last twelve months the share price has gained 237.8%, trading between 1.01 and 5.78.
Tweenvest scores Ironwood Pharmaceuticals, Inc. across four factors: quality 69/100, value 80/100, growth 28/100. Its strongest factor is value.
IRWD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $708.88M
- Revenue (TTM)
- $389.32M
- P/E
- 5.44
- EPS
- 0.79
- Dividend yield
- —
- Beta (5Y)
- 0.21
- 52-week high
- $5.78
- 52-week low
- $1.01
- Avg volume (3M)
- —
- Shares outstanding
- 165.24M
- Employees
- 100
- Next earnings
- —
About Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
- ISIN
- US46333X1081
- Founded
- 1998
- Listed since
- Feb 3, 2010
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $266.14 | +0.45% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.50 | +0.27% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.69 | +0.39% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.14 | +0.01% |
| argenx SEENXTBR: ARGX | $65.85B | €882.20 | -2.20% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.01 | -1.42% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.